YARDLEY, PA & LONDON — Herspiegel has announced a major step in its strategic growth by partnering with FIECON, a leading European health economics and market access consultancy, to enhance its global commercialization and access services.
This alliance significantly bolsters Herspiegel’s ability to deliver cutting-edge health economic modeling, outcomes research, Health Technology Assessments (HTAs), pricing and reimbursement strategies, and Real-World Evidence (RWE) solutions. By integrating FIECON’s deep expertise, the combined firm is poised to drive patient access to life-saving therapies across global markets.
The partnership expands Herspiegel’s footprint with FIECON’s London-based team and leverages FIECON’s impressive success rate of over 95% in securing HTA approvals. With added capabilities around Joint Clinical Assessments (JCA), the collaboration strengthens support for navigating complex regulatory landscapes in Europe and beyond.
Herspiegel’s CEO, Brent Herspiegel, highlighted the milestone, stating, “Bringing together our commercialization expertise with FIECON’s exceptional capabilities in health economics and HTA strengthens our ability to guide clients through complex regulatory and market access challenges. We are committed to delivering integrated, data-driven solutions that enhance commercial success globally.”
FIECON’s CEO, Kuntal Fisher, expressed similar enthusiasm, noting, “Our shared vision of delivering high-quality, evidence-based solutions makes this partnership a natural fit. Together, we are expanding our ability to use economics for the good of humanity, supporting clients with greater resources and strategic insights.”
The collaboration brings together over 250 professionals to deliver end-to-end commercialization services for pharmaceutical and biotech organizations worldwide. With the growing need for robust economic evidence in regulatory and reimbursement approvals, the strengthened Herspiegel-FIECON partnership sets a new benchmark for global market access, enhancing patient experiences and access to innovative therapies.
Piper Sandler & Co. served as the exclusive financial advisor to FIECON, with Bird & Bird LLP providing legal counsel.
Herspiegel Expands Global Market Access Capabilities with FIECON Partnership
YARDLEY, PA & LONDON – Herspiegel has announced a major step in its strategic growth by partnering with FIECON, a leading European health economics and market access consultancy, to enhance its global commercialization and access services.
This alliance significantly bolsters Herspiegel’s ability to deliver cutting-edge health economic modeling, outcomes research, Health Technology Assessments (HTAs), pricing and reimbursement strategies, and Real-World Evidence (RWE) solutions. By integrating FIECON’s deep expertise, the combined firm is poised to drive patient access to life-saving therapies across global markets.
The partnership expands Herspiegel’s footprint with FIECON’s London-based team and leverages FIECON’s impressive success rate of over 95% in securing HTA approvals. With added capabilities around Joint Clinical Assessments (JCA), the collaboration strengthens support for navigating complex regulatory landscapes in Europe and beyond.
Herspiegel’s CEO, Brent Herspiegel, highlighted the milestone, stating, “Bringing together our commercialization expertise with FIECON’s exceptional capabilities in health economics and HTA strengthens our ability to guide clients through complex regulatory and market access challenges. We are committed to delivering integrated, data-driven solutions that enhance commercial success globally.”
FIECON’s CEO, Kuntal Fisher, expressed similar enthusiasm, noting, “Our shared vision of delivering high-quality, evidence-based solutions makes this partnership a natural fit. Together, we are expanding our ability to use economics for the good of humanity, supporting clients with greater resources and strategic insights.”
The collaboration brings together over 250 professionals to deliver end-to-end commercialization services for pharmaceutical and biotech organizations worldwide. With the growing need for robust economic evidence in regulatory and reimbursement approvals, the strengthened Herspiegel-FIECON partnership sets a new benchmark for global market access, enhancing patient experiences and access to innovative therapies.
Piper Sandler & Co. served as the exclusive financial advisor to FIECON, with Bird & Bird LLP providing legal counsel.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.